Active Biotech AB (publ)

Active Biotech AB (publ) is a Swedish biotechnology firm focused on developing pharmaceutical treatments for oncology and immunological conditions. Its product pipeline features Tasquinimod, a small molecule immunomodulator currently in Phase Ib/IIa clinical trials for treating multiple myeloma. Another key asset is Laquinimod, an immunomodulator undergoing Phase I development for various inflammatory eye disorders, including uveitis. Additionally, the company is advancing Naptumomab, an anti-cancer immunotherapy, which is in Phase Ib/II clinical trials for individuals with advanced solid tumors. Naptumomab's development and commercialization are managed through a licensing partnership with NeoTX Therapeutics Ltd. Founded in 1983, Active Biotech AB (publ) is headquartered in Lund, Sweden.